Allen, N.E.* ; Travis, R.C.* ; Appleby, P.N.* ; Albanes, D.* ; Barnett, M.J.* ; Black, A.* ; Bueno-de-Mesquita, H.B.* ; Deschasaux, M.* ; Galan, P.* ; Goodman, G.E.* ; Goodman, P.J.* ; Gunter, M.J.* ; Heliövaara, M.* ; Helzlsouer, K.J.* ; Henderson, B.E.* ; Hercberg, S.* ; Knekt, P.* ; Kolonel, L.N.* ; Lasheras, C.* ; Linseisen, J. ; Metter, E.J.* ; Neuhouser, M.L.* ; Olsen, A.* ; Pala, V.* ; Platz, E.A.* ; Rissanen, H.* ; Reid, M.E.* ; Schenk, J.M.* ; Stampfer, M.J.* ; Stattin, P.* ; Tangen, C.M.* ; Touvier, M.* ; Trichopoulou, A.* ; van den Brandt, P.A.* ; Key, T.J.*
Selenium and prostate cancer: Analysis of individual participant data from fifteen prospective studies.
J. Natl. Cancer Inst. 108:djw153 (2016)
BACKGROUND: Some observational studies suggest that a higher selenium status is associated with a lower risk of prostate cancer but have been generally too small to provide precise estimates of associations, particularly by disease stage and grade. METHODS: Collaborating investigators from 15 prospective studies provided individual-participant records (from predominantly men of white European ancestry) on blood or toenail selenium concentrations and prostate cancer risk. Odds ratios of prostate cancer by selenium concentration were estimated using multivariable-adjusted conditional logistic regression. All statistical tests were two-sided. RESULTS: Blood selenium was not associated with the risk of total prostate cancer (multivariable-adjusted odds ratio [OR] per 80 percentile increase = 1.01, 95% confidence interval [CI] = 0.83 to 1.23, based on 4527 case patients and 6021 control subjects). However, there was heterogeneity by disease aggressiveness (ie, advanced stage and/or prostate cancer death, Pheterogeneity = .01), with high blood selenium associated with a lower risk of aggressive disease (OR = 0.43, 95% CI = 0.21 to 0.87) but not with nonaggressive disease. Nail selenium was inversely associated with total prostate cancer (OR = 0.29, 95% CI = 0.22 to 0.40, Ptrend < .001, based on 1970 case patients and 2086 control subjects), including both nonaggressive (OR = 0.33, 95% CI = 0.22 to 0.50) and aggressive disease (OR = 0.18, 95% CI = 0.11 to 0.31, Pheterogeneity = .08). CONCLUSIONS: Nail, but not blood, selenium concentration is inversely associated with risk of total prostate cancer, possibly because nails are a more reliable marker of long-term selenium exposure. Both blood and nail selenium concentrations are associated with a reduced risk of aggressive disease, which warrants further investigation.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publication type
Article: Journal article
Document type
Scientific Article
Thesis type
Editors
Keywords
Serum Selenium; Subsequent Risk; Selenoprotein P; Trial; Association; Toenails; Men; Supplementation; Prevention; Polymorphisms
Keywords plus
Language
english
Publication Year
2016
Prepublished in Year
HGF-reported in Year
2016
ISSN (print) / ISBN
0027-8874
e-ISSN
1460-2105
ISBN
Book Volume Title
Conference Title
Conference Date
Conference Location
Proceedings Title
Quellenangaben
Volume: 108,
Issue: 11,
Pages: ,
Article Number: djw153
Supplement: ,
Series
Publisher
Oxford University Press
Publishing Place
Cary
Day of Oral Examination
0000-00-00
Advisor
Referee
Examiner
Topic
University
University place
Faculty
Publication date
0000-00-00
Application date
0000-00-00
Patent owner
Further owners
Application country
Patent priority
Reviewing status
Peer reviewed
Institute(s)
Institute of Epidemiology (EPI)
POF-Topic(s)
30202 - Environmental Health
Research field(s)
Genetics and Epidemiology
PSP Element(s)
G-504000-007
Grants
Copyright
Erfassungsdatum
2016-07-09